Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice

Virology Journal

Volumn 3, Issue , 2006, Pages

  Prichard, Mark N ^a   Quenelle, Debra C ^a   Bidanset, Deborah J ^a   Komazin, Gloria ^c   Chou, Sunwen ^b   Drach, John C ^c   Kern, Earl R ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOMEGALOVIRUS; IN VIVO STUDY; MOUSE; NONHUMAN; OPEN READING FRAME; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; CYTOMEGALOVIRUS; GENE DELETION; HUMANS; LIVER; LIVER TRANSPLANTATION; MICE; MICE, SCID; RETINA; THYMUS GLAND; VIRAL PROTEINS; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 33646376659     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-3-18     Document Type: Article

References (13)

1. Sia IG, Patel R: New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000, 13(1):83-121, table of contents.
2. McGavin JK, Goa KL: Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001, 61(8):1153-1183.
3. Gilbert C, Boivin G: Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005, 49(3):873-883.
4. Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S, Jacobson MA, Drew WL: Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002, 46(9):2969-2976.
5. McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK: Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol 2001, 8(6):1279-1281.
6. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW: Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002, 46(8):2365-2372.
7. Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM, Parker BO, Pari GS: A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999, 73(7):5663-5670.
8. Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER: In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003, 47(7):2186-2192.
9. Prichard MN, Britt WJ, Daily SL, Hartline CB, Kern ER: Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol 2005, 79(24):15494-15502.
10. Chou S, Marousek GI, Senters AE, Davis MG, Biron KK: Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 2004, 78(13):7124-7130.
11. Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC: Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol 2003, 77(21):11499-11506.
12. Montague MG, Hutchison CA: Gene content phylogeny of herpesviruses. Proc Natl Acad Sci U S A 2000, 97(10):5334-5339.
13. Kern ER, Rybak RJ, Hartline CB, Bidanset DJ: Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections. Antivir Chem Chemother 2001, 12 Suppl 1:149-156.